Vosoritide
CAS 1356308-64-4 2 FDA-DMF suppliersPeptide
Overview
Vosoritide is a peptide drug developed for the treatment of achondroplasia, a common form of dwarfism. It works by targeting the natriuretic peptide receptor to modulate the growth signaling pathways.
Patent & exclusivity (US)
Per the FDA Orange Book (3 approved US products), the latest listed US patent on Vosoritide expires 10 Jul 2042 and exclusivity 19 Oct 2030. Generic API sourcing typically opens up once these lapse.
Therapeutic areas
Genetic DisordersSkeletal DisordersGrowth Disorders
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.